Flawed evidence underpins approval of new cancer drugs

被引：11
|
作者：
Mintzes, Barbara [1 ,2 ]
Vitry, Agnes [3 ]
机构：
[1] Univ Sydney, Fac Med & Hlth, Sch Pharm, Sydney, NSW 2006, Australia
[2] Univ Sydney, Fac Med & Hlth, Charles Perkins Ctr, Sydney, NSW 2006, Australia
[3] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2019年 / 366卷
关键词：
SURROGATE END-POINTS; AMERICAN SOCIETY; ONCOLOGY; ASSOCIATION; SURVIVAL; STRENGTH;
D O I：
10.1136/bmj.l5399
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022
    Luo, Xingxian
    Du, Xin
    Huang, Lin
    Guo, Qixiang
    Lv, Xufeng
    Wang, Cen
    Liu, Haopeng
    Zhou, Yue
    Xue, Xuecai
    Li, Zhuangqi
    Liu, Jingwen
    Chow, Shein-Chung
    Yang, Yue
    ECLINICALMEDICINE, 2023, 63
  • [2] Accelerated Approval of Cancer Drugs-Righting the Ship of the US Food and Drug Administration
    DiMagno, Sarah S. P.
    Glickman, Aaron
    Emanuel, Ezekiel J.
    JAMA INTERNAL MEDICINE, 2019, 179 (07) : 922 - 923
  • [3] New concepts for approval of drugs in oncology beyond randomized clinical studies
    Michels, Sebastian
    Wolf, Juergen
    Hallek, Michael
    ONKOLOGE, 2019, 25 : 83 - 89
  • [4] Generating comparative evidence on new drugs and devices before approval
    Naci, Huseyin
    Salcher-Konrad, Maximilian
    Kesselheim, Aaron S.
    Wieseler, Beate
    Rochaix, Lise
    Redberg, Rita F.
    Salanti, Georgia
    Jackson, Emily
    Garner, Sarah
    Stroup, T. Scott
    Cipriani, Andrea
    LANCET, 2020, 395 (10228) : 986 - 997
  • [5] Generating comparative evidence on new drugs and devices after approval
    Cipriani, Andrea
    Ioannidis, John P. A.
    Rothwell, Peter M.
    Glasziou, Paul
    Li, Tianjing
    Hernandez, Adrian F.
    Tomlinson, Anneka
    Simes, John
    Naci, Huseyin
    LANCET, 2020, 395 (10228) : 998 - 1010
  • [6] Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
    Kato, Satoshi
    Ono, Shunsuke
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2024, 19 (05)
  • [7] Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
    Gyawali, Bishal
    Hey, Spencer Phillips
    Kesselheim, Aaron S.
    JAMA INTERNAL MEDICINE, 2019, 179 (07) : 906 - 913
  • [8] Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
    Gyawali, Bishal
    Hey, Spencer P.
    Kesselheim, Aaron S.
    ECLINICALMEDICINE, 2020, 21
  • [9] Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China
    Luo, Xingxian
    Xu, Yang
    Du, Xin
    Lv, Xufeng
    Chen, Si
    Yang, Yue
    Huang, Lin
    Zhang, Xiaohong
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 52
  • [10] Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
    Strand, G. Chauca
    Bonander, C.
    Jakobsson, N.
    Johansson, N.
    Svensson, M.
    ESMO OPEN, 2022, 7 (05)
12345